11-16 September 2011 The Unlimited World of Microbes

XV International Congress of Virology
VI-SY3-5 THE GD1A GLYCAN IS A CELLULAR RECEPTOR FOR ADENOVIRUSES CAUSING EPIDEMIC
KERATOCONJUNCTIVITIS
Niklas Arnberg 1 , Emma Nilsson 1 , Rickard Storm 1 , Johannes Bauer 2 ,
Susanne MC Johansson 1 , Aivar Lookene 3 , Lars Frangsmyr 1 , Simon Rinaldi 4 ,
Hugh J Willison 4 , Fatima Pedrosa Domellof 5 , Thilo Stehle 2
1 Department of Clinical Microbiology, Umea University, Sweden, 2 Interfaculty Institute of Biochemistry,
University of Tuebingen, 3 Department of Chemistry, Tallin University of Technology, 4 Institute of Infection,
Immunity and Infl ammation, University of Glasgow, 5 Departments of Clinical Sciences and Integrative
Medical Biology, Umea University
VI-SY3-6 NEWLY IDENTIFIED VARICELLA-ZOSTER VIRUS (VZV) ENTRY RECEPTOR EXPRESSED IN
HEMATOPOIETIC CELLS
Tadahiro Suenaga 1 , Fuminori Arisawa 1 , Yasuko Mori 3,4 , Hisashi Arase 1,2
1 Department of Immunochemistry, Research Institute for Microbial Diseases, Osaka University, Japan,
2 Immunochemistry, WPI Immunology Frontier Research Center, Osaka University, 3 Division of Clinical Virology,
Kobe University Graduate School of Medicine, 4 Laboratory of Virology and Vaccinology, Department of
Biomedical Research, National Institute of Biomedical Innovation
Monday, 12 September 11:25-12:55 Room F
VI-SY4 Viruses as Oncolytic Agents
Convener: Tomoki Todo Japan
VI-SY4-1 MUTATIONS IN THE GLYCOPROTEIN OF VESICULAR STOMATITIS VIRUS AFFECT
CYTOPATHOGENICITY: POTENTIAL FOR ONCOLYTIC VIROTHERAPY
Valerie Janelle 1,2 , Frederick Brassard 2 , Pascal Lapierre 1 , Laurent Poliquin 1,2 ,
Alain Lamarre 1,2
1 2
Immunovirology, INRS-Institut Armand-Frappier, Canada, Biomed Research Center, Department of Biology,
UQAM
VI-SY4-2 MICRORNA REGULATION OF GLYCOPROTEIN B5R IN ONCOLYTIC VACCINIA VIRUS
REDUCES VIRAL PATHOGENICITY WITHOUT IMPAIRING ITS ANTITUMOR EFFICACY
Mina Hikichi 1 , Minoru Kidokoro 2 , Hisatoshi Shida 3 , Hideaki Tahara 1 ,
Takafumi Nakamura 1,4
1 Core Facility for Therapeutic Vectors, Institute of Medical Science, University of Tokyo, Japan, 2 National
Institute of Infectious Diseases, 3 Institute for Genetic Medicine, Hokkaido University, 4 PRESTO, Japan Science
and Technology Agency
VI-SY4-3 ALTERED VIRAL TROPISM ON STEM CELLS AND SCID PATHOGENESIS BY S1 MUTATION
OF ONCOLYTIC REOVIRUS
Manbok Kim 1 , Garant Katy 2 , Patrick Lee 2 , Young-Seok Kim 3 , Randal N Johnston 4
1 Kinomics-Based Anticancer Research Center, Korea Research Institute of Bioscience and Biotechnology,
Korea, South, 2 Dalhousie University, Dept of Microbiol & Immunol, 3 Department of Radiation Oncology,
Asan Medical Center, University of Ulsan, College of Medicine, 4 University of Calgary, Dept of Biochem &
Molec Biol
VI-SY4-4 TUMOUR VASCULATURE IS CRITICAL FOR VACCINIA VIRUS THERAPY OF PERITONEAL
CARCINOMATOSIS
Kathryn Ottolino-Perry 1 , Nan Tang 2 , Renee Head 2 , Calvin Ng 2 , Fernando Angarita 1 ,
Sergio Acuna 1 , Ralph Dacosta 3 , J Andrea McCart 1,2,4
1 Institute of Medical Science, University of Toronto, Canada, 2 Division of Experimental Therapeutics, Toronto
General Research Institute, University Health Network, 3 Department of Medical Biophysics, Ontario Cancer
Institute, University Health Network, 4 Division of General Surgery, Department of Surgery, Mount Sinai
Hospital and University of Toronto
Monday, 12 September 11:25-12:55 Room H
VI-SY5 Vaccines
Convener: Duane J Gubler Singapore
VI-SY5-1 NEUTRALIZING EPITOPES OF INFLUENZA VIRUS HEMAGGLUTININ: TARGET FOR THE
DEVELOPMENT OF A UNIVERSAL VACCINE AGAINST H5N1 LINEAGES
Fang He, Mookkan Prabakaran, Jimmy Kwang
Animal Health Biotechnology, Temasek Life Sciences Laboratory, Singapore
49
Symposium
Monday, 12 September